Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Erytech Pharma has signed a licensing agreement granting commercialization and distribution rights of Graspa to Orphan Europe in the Europe.
Subscribe to our email newsletter
Graspa, which consists of L-asparaginase entrapped into human red blood cells, is developed as medication for hematological malignancies.
The product is being studied in pivotal Phase II/III acute lymphoblastic leukemia trial and will be advanced into a Phase IIb trial in acute myeloid leukemia in Europe.
Erytech chief executive officer Pierre-Olivier Goineau said, "This agreement is a major milestone for Erytech, and a clear recognition of the potential of our technology. It will allow us to focus on our developments in the US, in solid tumors and in other rare disease indications."
Graspa, which will be manufactured by Erytech, received orphan designation in Europe and the US for all indications, according to Erytech.
Orphan Europe CEO Marco Liguori said, "The Orphan Europe team has considerable experience in the orphan drug field and the special requirements of rare diseases."